Dynatronics reported financial results for its fourth quarter and fiscal year ended June 30, 2022, and provided an update on recent business highlights.

Non-invasive Parkinson’s therapeutic device moves one step closer to FDA clearance, with important potential non-motor and motor improvements for patients. The maker of the widely anticipated Celeste® specialized phototherapy device, PhotoPharmics, today announced plans to begin recruitment for the Celeste Light for PD trial in December. “Multiple forces have aligned to make the timing for […]

The nView s1 has just surpassed its landmark 100th clinical case with the help of 22 surgeons at six leading pediatric facilities, including three of the top 10 facilities in the nation.

Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards’ breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.

Salt Lake City, Utah /PRNewswire/ — Inherent Biosciences, the first Utah company involved in commercializing a diagnostic in the emerging biotech field of epigenetics, has raised Series A funding from an investor group led by Los Angeles-based Propel Bio Partners toward Inherent’s goal of changing the course of reproductive health. Inherent seeks to redefine the […]

Last week, BioHive kicked off its celebration of “STEM September” with an evening of networking in downtown Salt Lake City. Life sciences professionals joined from all over the Salt Lake Valley to connect with the industry and support the efforts of BioHive. “I was so inspired hearing stories from the people that make Utah’s life […]

Utah life sciences companies took center stage September 2, as U.S. Representative Burgess Owens (R-UT) toured Canyon Labs, Ultradent (Canyon Labs’ parent company), Ortho Development and Xenter – all innovative leaders in advancing medical technologies that improve patient care and provide jobs for hundreds of Utahns. BioUtah helped to facilitate the BioHive day. “Utah is […]

New Liquid Embolic Multi-Center Trial Successfully Enrolls Final Patient GPX® Trial Completes Enrollment Demonstrating Successful Tumor Uses and Other Applications Fluidx Medical announces completion of trial enrollment for its novel embolic device, GPX. In this multi-center trial, GPX was used to treat a variety of primary and metastatic tumors, renal adenoma tumors, and a range […]